cas 2641451-43-4|| where to buy 5-Bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-2-iodo-1H-indole

製品名:5-Bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-2-iodo-1H-indole

IUPAC Name:5-bromo-3-{3-[(tert-butyldiphenylsilyl)oxy]-2,2-dimethylpropyl}-2-iodo-1H-indole

包装単位	有効在庫	価格（USD）
CM1069437-250mg	in stock	ȃĲǵ
CM1069437-1g	in stock	ƥǵŉ
CM1069437-5g	in stock	ŉǤŹ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2641451-43-4 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:2641451-43-4; 分子式:C29H33BrINOSi; 融点:-; SMILESコード:IC(N1)=C(CC(C)(C)CO[Si](C2=CC=CC=C2)(C(C)(C)C)C3=CC=CC=C3)C4=C1C=CC(Br)=C4; 密度:

: カタログ番号:CM1069437; 分子量:646.48; 沸点:; MDL番号:; 保管方法:Keep in dark place,Inert atmosphere,2-8°C.

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.; indole company; As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

: RMC-6236; Over 30% of all human cancers, including a certain percentage of pancreatic, colorectal, lung cancers, and AML are driven by mutations of RAS genes. There is a significant unmet medical need in RAS mutant cancers.
Revolution Medicines’ investigational drug, RMC-6236 is an oral, non-covalent, RAS (ON) inhibitor that is selective for the active, GTP-bound state of both mutant and wild-type variants of the canonical RAS isoforms. RMC-6236 is under clinical phase I studies as monotherapy in NSCLC and PDAC, and advanced solid tumors harboring KRAS G12X mutations.